Events
The U.S. Food and Drug Administration granted approval of Biogen’s aducanumab for the treatment of Alzheimer’s disease.
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
After three years, 85.9% of patients treated post-surgically with Lynparza were free of invasive breast cancer and second cancers compared to 77.1% of the placebo group.
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
Today, the Swiss pharma titan announced the results of its Phase III VISION study, where 177Lu-PSMA-617 plus best standard of care (SOC) met both of its primary endpoints.
Alzheimer’s patients and their families wait with hope that this will mean some offer of treatment, while physicians that treat Alzheimer’s patients are mulling the implications of the drug, often with hesitancy and skepticism.
BioSpace continues to take a look at some of the data that will be shared at the 2021 ASCO meeting. Here are some of them.
To develop and commercialize them with maximum efficiency, the FDA, scientists and developers must innovate, according to panelists speaking during the Presidential Plenary on Commercialization at the International Society of Cell & Gene Therapy on May 26.
PRESS RELEASES